




Medical

Posidyne® ELD Filter



Air-eliminating filter designed for 96-hour particle, bacteria and endotoxin retention

Features

- ▶ Removes particles
- ▶ Retains microorganisms and associated endotoxins
- ▶ Eliminates air
- ▶ Non-phthalate fluid pathway
- ▶ Slim housing profile

Benefits

- ▶ Protects patients against particle-related risks
- ▶ 96-hour life on filter and set reduces cost of IV therapy and minimizes nursing time and set manipulations
- ▶ Minimizes air emboli
- ▶ Suitable for paclitaxel delivery
- ▶ Simple to tape in place

Filtration. Separation. Solution.SM

Inadvertent Contamination of Infusion Solutions Can Have Serious Consequences

- ▶ Particulate contamination arises from a variety of sources, intrinsically in infusates and equipment or extrinsically due to manipulations.¹ Particles cause phlebitis on peripheral infusion lines and have serious systemic effects, damaging the lung and solid organs by irritation of the endothelium and by deposition in the microvasculature².
- ▶ Microbiological contamination of IV administration systems arises inadvertently due to manipulations³. Some bacteria can grow rapidly in infusion fluids, increasing the infection risk⁴.
- ▶ Endotoxins have serious effects on the inflammatory and coagulation systems. They are released by Gram-negative bacteria and have been shown to penetrate conventional IV filters⁵. Only filters that retain endotoxins can safely be used for more than 24 hours⁵.
- ▶ Entrained air can arise from infusion solutions degassing, incomplete priming or disconnections. Air can be particularly problematic on central lines, leading to air embolism, which can be fatal⁶.

Specifications

Filter Media

0.2 µm positively charged Nylon Posidyne® membrane

Filters and Tubing Extension

Non-phthalate, free of natural rubber latex

Dimensions (approximate)

Length = 6.9 cm

Width = 3.6 cm

Depth = 0.7 cm

Connectors

Male luer lock outlet and female luer lock inlet

Filter Housing Volume

Approximately 2 mL

Approximate Total Hold-up Volume

ELD96NT*, ELD96NTE**	2.0 mL
ELD96LLCE**	2.6 mL
ELD96LL*	2.7 mL
ELD96LYL*, ELD96LYLE**, ELD96NY*	2.8 mL (including volume from Y-site to tubing outlet of 0.3 mL)
ELD96NYS*	4.3 mL (including volume from Y-site to tubing outlet of 1.0 mL)
ELD96LYLS*, ELD96LYLSE**	4.3 mL (including volume from Y-site to tubing outlet of 1.2 mL)

*Intended for distribution or use in the USA.

**Intended for distribution or use in Europe.

Sterility

Sterile and non-pyrogenic fluid pathway

Maximum Flow Rate***

Variants with standard bore extension tubing:

approximately 21-23 mL/min

ELD96NYS approximately 35 mL/min

Variants with microbore extension tubing:

approximately 13-14 mL/min

ELD96NY approximately 18.5 mL/min

Maximum Working Pressure

1500 mm Hg (approximately 30 psi, 2 bar)

Usage Specifications

Single patient use up to 96 hours

Can be used with continuous infusions or intermittent infusions/injections

***Tested under gravity with 0.9% saline solution at 1 m head height.

Ordering Information

Product Description	Reorder Code		Packaging (Units/Case)	
	USA Only	Europe Only	USA	Europe
With microbore extension tubing	ELD96LL	ELD96LLCE ¹	48	50
With microbore extension tubing and Y injection site	ELD96LYL	ELD96LYLE ¹	48	50
With microbore extension tubing and needleless Y injection site	ELD96NY	—	48	—
With standard bore extension tubing and Y injection site	ELD96LYLS	ELD96LYLSE ¹	48	50
With standard bore extension tubing and needleless Y injection site	ELD96NYS	—	48	—
Without extension tubing	ELD96NT	ELD96NTE	40	40

¹with downstream slide clamp

References

1. Ball, P.A. (2003) Intravenous in-line filters: filtering the evidence. *Curr Opin Clin Nutr Metab Care*, 6:319-25.
2. Lehr, H.A. et al. (2002) Particulate matter contamination of intravenous antibiotics aggravates loss of functional capillary density in posts ischemic striated muscle. *Am J Respir Crit Care Med*, 165:514-20.
3. Trautmann, M. et al. (1997) Bacterial colonization and endotoxin contamination of intravenous infusion fluids. *J Hosp Infect*, 37:225-36.
4. Richards, C. & Thomas, P. (1990) Use of endotoxin retentive intravenous filters with pediatric total parenteral nutrition solutions. *J Clin Pharm Ther*, 15:53-8.
5. Richards, C. & Grassby, P.F. (1994) A comparison of the endotoxin-retentive abilities of two '96-h' in-line intravenous filters. *J Clin Pharm Ther*, 19:199-202.
6. Coppa, G.F. et al. (1981) Air embolism: a lethal but preventable complication of subclavian vein catheterization. *JPEN J Parenter Enteral Nutr*, 5:166-8.
7. Muth, C.M. & Shank, E.S. (2000) Gas embolism. *N Engl J Med*, 342 (7):476-482.



Pall Medical
25 Harbor Park Dr
Port Washington, NY 11050

516.484.3600 phone
medical.pall.com web
uscustomerservice@pall.com email

Europe
Pall Medical
a division of Pall Europe Ltd
Europa House, Havant Street
Portsmouth PO1 3PD, England
+44 (0)23 9230 3452 telephone
+44 (0)23 9230 3324 fax
Biosvc@Pall.com E-mail

Visit us on the Web at www.pall.com

International Offices

Pall Corporation has offices and plants throughout the world in locations such as: Argentina, Australia, Austria, Belgium, Brazil, Canada, China, France, Germany, Hong Kong, India, Indonesia, Ireland, Italy, Japan, Korea, Malaysia, Mexico, the Netherlands, New Zealand, Norway, Poland, Puerto Rico, Russia, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, the United Kingdom, the United States, and Venezuela. Distributors in all major industrial areas of the world.

The information provided in this literature was reviewed for accuracy at the time of publication. Product data may be subject to change without notice. For current information consult your local Pall distributor or contact Pall directly.

© 2007, Pall Corporation. Pall, and Posidyne are trademarks of Pall Corporation. ® indicates a registered trademark in the USA. Filtration. Separation. Solution.sm is a service mark of Pall Corporation.